Siponimod and Cognition in Secondary Progressive Multiple Sclerosis EXPAND Secondary Analyses

被引:57
作者
Benedict, Ralph H. B. [1 ]
Tomic, Davorka [2 ]
Cree, Bruce A. [3 ]
Fox, Robert [4 ]
Giovannoni, Gavin [5 ]
Bar-Or, Amit [6 ]
Gold, Ralf [7 ]
Vermersch, Patrick [8 ]
Pohlmann, Harald [2 ]
Wright, Ian [9 ]
Karlsson, Goril [2 ,11 ,12 ,13 ,14 ,15 ]
Dahlke, Frank [2 ]
Wolf, Christian [10 ]
Kappos, Ludwig [11 ,12 ,13 ,14 ,15 ]
机构
[1] Univ Buffalo, Dept Neurol, Buffalo, NY 14260 USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA
[4] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH USA
[5] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England
[6] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA
[7] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany
[8] Univ Lille, INSERM U1172, CHU Lille, FHU Imminent,Dept Neurol, Lille, France
[9] Novartis Ireland Ltd, Dublin, Ireland
[10] Lycalis sprl, Brussels, Belgium
[11] Univ Hosp, Dept Med, Basel, Switzerland
[12] Univ Hosp, Dept Clin Res, Basel, Switzerland
[13] Univ Hosp, Dept Biomed, Basel, Switzerland
[14] Univ Hosp, Dept Biomed Engn, Basel, Switzerland
[15] Univ Basel, Basel, Switzerland
关键词
INFORMATION-PROCESSING SPEED; DIGIT MODALITIES TEST; INTERFERON BETA-1A; PERFORMANCE; RELIABILITY; PASAT; THALAMUS; ATROPHY; DEFICIT; TRIALS;
D O I
10.1212/WNL.0000000000011275
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To investigate the effects of siponimod on cognitive processing speed in patients with secondary progressive (SP) multiple sclerosis (MS), bymeans of a predefined exploratory and post hoc analysis of the Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) study, a randomized controlled trial comparing siponimod and placebo. Methods EXPAND was a double-blind, placebo-controlled phase 3 trial involving 1,651 patients with SPMS randomized (2:1) to either siponimod 2 mg/d or placebo. Cognitive function was assessed with the Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), and Brief Visuospatial Memory Test-Revised (BVMT-R) administered at baseline, 6-month intervals, and end of treatment. Results Between-group differences in mean change from baseline in SDMT scores were significantly better in siponimod- vs placebo-treated patients at month 12 (difference 1.08 [95% confidence interval 0.23-1.94]; p = 0.0132), month 18 (1.23 [0.25-2.21); p = 0.0135), and month 24 (2.30 [1.11-3.50]; p = 0.0002). Siponimod-treated patients were at significantly lower risk for having a 4-point sustained decrease in SDMT score (hazard ratio [HR] 0.79 [0.65-0.96]; p = 0.0157), while their chance for having a 4-point sustained increase in SDMT score was higher (HR 1.28 [1.05-1.55]; p = 0.0131). PASAT and BVMT-R scores did not differ significantly between the 2 treatment groups (all p > 0.28). Conclusion Siponimod had a significant benefit on SDMT in patients with SPMS. Siponimod-treated patients were at significantly lower risk for having a >= 4-point decrease in SDMT score and had a significantly higher chance for having a >= 04-point increase in SDMT score, a magnitude of change accepted as clinically meaningful. Classification of Evidence This study provides Class II evidence that, for patients with SPMS, siponimod had a significant benefit on cognitive processing speed.
引用
收藏
页码:E376 / E386
页数:11
相关论文
共 61 条
[1]  
Arnold DA, 2019, 35 C EUR COMM TREATM, P382
[2]  
Aslanis V, 2012, MULT SCLER J, V18, P355
[3]   Within session practice effects on the PASAT in clients with multiple sclerosis [J].
Barker-Collo, SL .
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2005, 20 (02) :145-152
[4]  
Benedict R.H. B., 2012, NINDS common data elements, multiple sclerosis, neuropsychology/cognition recommendations
[5]   Neuropsychology of Multiple Sclerosis: Looking Back and Moving Forward [J].
Benedict, Ralph H. B. ;
DeLuca, John ;
Enzinger, Christian ;
Geurts, Jeroen J. G. ;
Krupp, Lauren B. ;
Rao, Stephen M. .
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2017, 23 (9-10) :832-842
[6]   Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study [J].
Benedict, Ralph H. B. ;
Cohan, Stanley ;
Lynch, Sharon G. ;
Riester, Katherine ;
Wang, Ping ;
Castro-Borrero, Wanda ;
Elkins, Jacob ;
Sabatella, Guido .
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) :795-804
[7]   Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis [J].
Benedict, Ralph H. B. ;
DeLuca, John ;
Phillips, Glenn ;
LaRocca, Nicholas ;
Hudson, Lynn D. ;
Rudick, Richard .
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (05) :721-733
[8]   Characterizing cognitive function during relapse in multiple sclerosis [J].
Benedict, Ralph H. B. ;
Morrow, Sarah ;
Rodgers, Jonathan ;
Hojnacki, David ;
Bucello, Margaret A. ;
Zivadinov, Robert ;
Weinstock-Guttman, Bianca .
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (13) :1745-1752
[9]   Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials [J].
Benedict, Ralph H. B. ;
Smerbeck, Audrey ;
Parikh, Rajavi ;
Rodgers, Jonathan ;
Cadavid, Diego ;
Erlanger, David .
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (09) :1320-1325
[10]   Revision of the brief visuospatial memory test: Studies of normal performance, reliability, and validity [J].
Benedict, RHB ;
Schretlen, D ;
Groninger, L ;
Dobraski, M ;
Shpritz, B .
PSYCHOLOGICAL ASSESSMENT, 1996, 8 (02) :145-153